Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai Aims at 120 Billion Yen Sales for Lenvima: CEO Naito
March 6, 2015
- MSD Japan Sales Down 14%, Januvia Sags 6.7%
March 6, 2015
- Kyowa Kirin Initiates PII Study of Bardoxolone Methyl in Japan
March 6, 2015
- Opdivo Approved for Lung Cancer in US
March 6, 2015
- Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
- Merck Japan Names Ralf Annasentz as New President
March 5, 2015
- Sanwa Kagaku to Promote Katsumi Hata as New President
March 5, 2015
- Toray Files Remitch Capsules for Pruritus in Chronic Liver Disease
March 5, 2015
- GSK, Novartis Unveil Details of 3-Part Asset Swap Deal in Japan
March 4, 2015
- Weber to Become CEO of Takeda in April
March 4, 2015
- Announcement: 12th Annual BIO Asia International Conference to Be Held on March 24, 25
March 4, 2015
- Japan Units of Abbott, Mylan to Run Separate Operations for Now
March 4, 2015
- Almac Aims to Expand Japan Business
March 4, 2015
- Santen Files Sirolimus for Noninfectious Uveitis in Europe
March 4, 2015
- Chugai, Athersys Join Hands for Cell Therapy Treatment
March 4, 2015
- Taiho Files Lonsurf for EU Approval
March 4, 2015
- Torii to Market 2 Anti-HIV Drugs Containing Tenofovir Alafenamide in Japan
March 3, 2015
- Switch OTC Drug Market Grows to 162 Billion Yen in 2014: Fuji Keizai
March 3, 2015
- Novartis Offers Apologies over Biz Suspension, Vows to Prevent Recurrence
March 2, 2015
- Jinarc Approved for Autosomal Dominant Polycystic Kidney Disease in Canada: Otsuka
March 2, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…